Skip to main content
OPRX
NASDAQ Trade & Services

OptimizeRx CFO Stelmakh to Exit; D'Silva and Favazza Promoted; Q2 Revenue Falls 30%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$7.04
Mkt Cap
$132.106M
52W Low
$4.54
52W High
$22.25
52W Position info
55% above low
Off High info
68% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

OPRX sits 55% above its 52-week low of $4.54.

Summary

OptimizeRx announced CFO Edward Stelmakh will step down at year-end, with Andrew D'Silva and Heather Favazza promoted to CFO and CAO. Q2 revenue fell 30% to $20.5 million, but adjusted EBITDA beat expectations and FY2026 guidance was reaffirmed.


Key Events · Executive and Board Changes · OPRX

  • CFO Transition Announced

    Edward Stelmakh will step down as CFO & Strategy Officer effective December 31, 2026, with a separation package including $450,000 salary continuation, $247,500 bonus, COBRA reimbursement, and continued equity vesting through a 12-month advisory term.

  • New Finance Leadership

    Andrew D'Silva becomes CFO and Heather Favazza becomes Chief Accounting Officer, both effective January 1, 2027. D'Silva's base salary is $375,000 with 50% target bonus; Favazza's is $325,000 with 40% target bonus.

  • Q2 Revenue Declines 30%

    Q2 2026 revenue was $20.5 million, down from $29.2 million in Q2 2025. GAAP net loss was $0.7 million, but adjusted EBITDA was $4.9 million, exceeding consensus expectations.

  • FY2026 Guidance Reaffirmed

    Management reiterated full-year 2026 guidance of $95-$100 million in revenue and $21-$25 million in adjusted EBITDA, citing first-half performance and commercial momentum.


Analysis · OPRX · Trade & Services

A planned CFO transition and Q2 results were disclosed in the same filing. CFO Edward Stelmakh will step down at year-end with a separation package worth roughly $700,000 in cash plus continued equity vesting, while Andrew D'Silva and Heather Favazza are promoted to CFO and CAO effective January 1, 2027. The earnings release shows revenue down 30% year-over-year to $20.5 million, though adjusted EBITDA of $4.9 million beat consensus and full-year guidance was reaffirmed. The CFO departure is a material governance event, and the revenue decline is significant, but the reaffirmed guidance and internal promotions suggest a planned, orderly transition rather than a crisis.

At the time of this filing, OPRX was trading at $7.04 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $132.1M. The 52-week trading range was $4.54 to $22.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OPRX - Latest Insights

OPRX
Aug 12, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
OPRX
Jun 12, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
OPRX
Jun 05, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
OPRX
Jun 01, 2026, 7:30 AM EDT
Filing Type: DEFA14A
Importance Score:
8
OPRX
May 13, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
7